3.4 Meta-analysis for mortality outcome:
The current meta-analysis results indicated that NOAF in the COVID-19
was associated with an increased mortality compared with COVID-19
patients presenting without NOAF or history of atrial fibrillation (OR=
3.83, 95% CI 2.99 to 4.92). The outcome had high associated
heterogeneity (I 2 = 87%). The result was pooled from 25 studies,
comprising 56,283 COVID-19 patients (Figure 4 A).
Similarly, our analysis revealed that COVID-19 patients with NOAF had an
increased mortality when compared with COVID-19 patients with a history
of pre-existing atrial fibrillation (OR= 2.32, 95% CI 1.35 to 3.96).
This outcome had high associated heterogeneity (I 2 = 87%). The
result was pooled from 13 studies, comprising 3,882 COVID-19 patients
(Figure 4 B).